MDNA11
As of the edition of 20 October 2026, MDNA11 is a drug known only by a code name: in active development; acts on IL2RA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Infections; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL2RA | Interleukin-2 receptor subunit alpha | P01589 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Medicenna Therapeutics | Lead sponsor of trials | 2021 to now |